Vaxxinity will continue developing vaccines for COVID-19 and neurological disorders, including Alzheimer's and Parkinson's diseases, as well as prevalent chronic disorders such as migraine and hypercholesterolemia.

The lead candidate in Vaxxinity's pipeline is UB-612, a vaccine candidate to fight SARS-CoV-2 that has shown some promise in phase I trials. The candidate uses COVAXX's proprietary synthetic peptide technology and is a multitope protein/peptide-based vaccine designed to activate B- and T-cell immune responses against SARS-CoV-2.

Vaxxinity's shipping partner, Maersk, will provide the capabilities to deliver hundreds of millions of UB-612 doses worldwide, using existing infrastructure.

COVAXX and United Neuroscience are now wholly owned subsidiaries of Vaxxinity. Lou Reese, executive chairman of COVAXX, has been appointed executive chairman of Vaxxinity, while Mei Mei Hu, CEO of COVAXX, has been appointed CEO of Vaxxinity.

GSK, Vir file EUA submission for COVID-19 mAb treatment
GlaxoSmithKline (GSK) and Vir Biotechnology filed an emergency use authorization (EUA) application with the U.S. Food and Drug Administration for VIR-7831...

Sanofi, GSK start phase II COVID-19 vaccine study
Sanofi and GlaxoSmithKline (GSK) are starting a large phase II study of their COVID-19 vaccine.

Covaxx reports positive phase I results for COVID-19 vaccine
Covaxx announced positive interim phase I data from its open-label COVID-19 clinical trial in Taiwan investigating UB-612, a multitope peptide-based vaccine...

Covaxx to deliver over 140M vaccine doses to emerging countries
Covaxx, a subsidiary of United Biomedical, has received purchase commitments of more than 140 million doses of its UB-612 COVID-19 vaccine, totaling...

ReiThera touts phase I COVID-19 vaccine results
ReiThera is highlighting positive phase I clinical trial results for its COVID-19 vaccine candidate, GRAd-COV2.